secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001808805-21-000016
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Q3 net loss widens to $14.5M; OpEx up 262%; cash at $374M
------------------------------------------------------------------

- Net loss of $14.5M for Q3 2021 vs. $4.0M loss in Q3 2020.
- Operating expenses $14.6M, up 262% YoY on higher headcount and public-company costs.
- Cash, cash equivalents and investments totaled $374.0M at September 30, 2021.
- Strategic partnership with Abcam and two new research collaborations (pharma and MD Anderson).
- Published theoretical foundation for PrISM single-molecule protein identification method.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880521000016/0001808805-21-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880521000016/naut-20211102.htm
  HTML page:      https://secwatch.observer/filing/0001808805-21-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer